Denna sida på svenska This page in English

Next generation immuno-oncological targets for cancer therapy

Principle investigator Kristina Lundberg



Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. The research focus of this position is to identify and explore novel immune cells and targets in cancer.


The overall aim of our research is to identify and exploit novel drug targets that enables the immune system to efficiently eradicate cancer cells, and to translate these findings into novel clinical strategies. We have established a pipeline for transcriptomic studies down to single-cell level of tumour-infiltrating immune cells using RNA sequencing, as well as for bioinformatical analysis of the data, to pinpoint novel potential cell surface drug targets on specific immune cells. We employ this pipeline to identify novel targets on e.g., specific T-cells and on cells that regulate T-cell activity, such as myeloid cells. Furthermore, we are involved in a project aiming to explore immune targets in combination with radiation treatment. Through an extensive network of national and international collaborators we explore these cells in several different cancer indications, including e.g. acute myeloid leukemia as well as bladder and prostate cancer.


We now offer a highly motivated postdoctoral candidate to join our team. Depending on project progression, there will be possibilities to perform research from target discovery, based e.g., on transcriptomic studies, to functional in vitro studies and beyond, using antibodies developed in-house against identified targets. Furthermore, spatial profiling to assess immune cell and target distribution within tissue may be part of the project. We work closely together with clinicians at Skåne University Hospital, enabling access to samples from cancer patients, and also together with the industry with Alligator Bioscience being a collaborator within projects.


Key requirements:


  • PhD in immunology/immuno-oncology/tumor immunology
  • Documented knowledge in immunology, preferably focused on human T-cells and/or myeloid cells 
  • Experience of primary cell work
  • Strong publication record
  • Very good communication skills and very good oral and written proficiency in English


Advantageous skills:

The project requires deep knowledge in immunology/immuno-oncology, especially within the field of T-cells and myeloid cells, and it is thus advantageous to have this already at the start of the project. Further on, the project will be based on a set of technologies/methods such as spatial profiling, functional in vitro assays, flow cytometry and cell sorting, as well as on advanced bioinformatical methods and R programming. Previous experience in relation to these aspects is thus a plus, but all of these skills are not required and consideration will then be taken to how the applicant’s skills and experiences complement existing competence within the group. Additionally, consideration will be given to the ability to summarize and present scientific data, both orally and in writing (in English) and to good collaborative skills, drive and independence.

Website:Kristina Lundberg

Partners: Region Skåne.